Leerink Partnrs Issues Positive Forecast for ALDX Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings estimate for Aldeyra Therapeutics to ($0.17) per share, an improvement from the previous forecast of ($0.23).
• Aldeyra Therapeutics reported ($0.16) earnings per share for its last quarter, surpassing the consensus estimate of ($0.21) by $0.05.
• Insider Stephen Machatha sold 22,073 shares of Aldeyra Therapeutics, decreasing his ownership by 9.05% after the transaction.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) - Investment analysts at Leerink Partnrs raised their Q3 2025 earnings estimates for Aldeyra Therapeutics in a note issued to investors on Monday, August 11th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their prior forecast of ($0.23). The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics' Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.70) EPS.

A number of other equities analysts have also weighed in on ALDX. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, May 19th. Wall Street Zen upgraded shares of Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st.

Aldeyra Therapeutics Stock Up 0.2%

Shares of NASDAQ ALDX opened at $5.37 on Thursday. Aldeyra Therapeutics has a 12-month low of $1.14 and a 12-month high of $7.20. The firm has a market cap of $321.66 million, a PE ratio of -6.32 and a beta of 0.76. The company's fifty day simple moving average is $4.30 and its 200 day simple moving average is $4.25.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05.

Insiders Place Their Bets

In other Aldeyra Therapeutics news, insider Stephen Machatha sold 22,073 shares of the business's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $5.15, for a total value of $113,675.95. Following the completion of the transaction, the insider directly owned 221,799 shares of the company's stock, valued at approximately $1,142,264.85. The trade was a 9.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 9.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new position in Aldeyra Therapeutics during the second quarter worth $25,000. Inspirion Wealth Advisors LLC purchased a new position in Aldeyra Therapeutics during the second quarter worth $38,000. Hsbc Holdings PLC purchased a new position in Aldeyra Therapeutics during the fourth quarter worth $52,000. Capital Advisors Wealth Management LLC purchased a new position in Aldeyra Therapeutics during the first quarter worth $62,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in Aldeyra Therapeutics during the first quarter worth $63,000. Hedge funds and other institutional investors own 59.71% of the company's stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.